News Releases

October 2018

October 1, 2018 10/1/2018 Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial

September 2018

September 28, 2018 9/28/2018 Takeda and Lundbeck Submit New Drug Application (NDA) for Vortioxetine in Japan for the Treatment of Major Depressive Disorder (MDD)

September 28, 2018 9/28/2018 Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

September 25, 2018 9/25/2018 Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial

September 21, 2018 9/21/2018 Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

September 21, 2018 9/21/2018 Takeda Obtains Additional Indication and Dosage & Administration for ADCETRIS® as a Frontline Treatment for CD30-positive Hodgkin Lymphoma in Japan

September 18, 2018 9/18/2018 Takeda Selected by the Dow Jones Sustainability Asia Pacific Index for the 9th Consecutive Year

September 14, 2018 9/14/2018 Takeda receives clearance from the State Administration for Market Regulation in China for the proposed acquisition of Shire plc

August 2018

August 9, 2018 8/9/2018 Ambys Medicines and Takeda Announce Partnership to Pioneer First-In-Class Therapies for the Treatment of Serious Liver Diseases